Compare SLAI & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
SOLAI Limited American Depositary Shares (each representing one hundred (100) Class A Ordinary Shares)
Current Price
| Metric | SLAI | HIND |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.1M | 28.0M |
| IPO Year | N/A | 2016 |
| Metric | SLAI | HIND |
|---|---|---|
| Price | $0.89 | $3.68 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 98.3K | N/A |
| Earning Date | 11-21-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,209,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.87 | N/A |
| 52 Week High | $8.07 | N/A |
| Indicator | SLAI | HIND |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 33.96 |
| Support Level | N/A | $3.62 |
| Resistance Level | N/A | $5.88 |
| Average True Range (ATR) | 0.00 | 0.37 |
| MACD | 0.00 | -0.07 |
| Stochastic Oscillator | 0.00 | 6.71 |
SOLAI Ltd is a technology-driven cryptocurrency infrastructure company. It is expanding from its foundation in crypto mining to build a blockchain-based ecosystem spanning AI, stablecoins, and payment infrastructure, and Solana treasury and staking operations supporting use cases across institutional settlement, commerce, consumer payments, and AI-native agent transactions. The group is leveraging its blockchain and data infrastructure expertise, aiming to enhance on-chain efficiency and expand participation across Solana and other blockchain ecosystems.
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.